You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 6,037,157

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,037,157

Title:	Method for improving pharmacokinetics
Abstract:	A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
Inventor(s):	Norbeck; Daniel W. (Crystal Lake, IL), Kempf; Dale J. (Libertyville, IL), Leonard; John M. (Lake Bluff, IL), Bertz; Richard J. (Kenosha, WI)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	08/687,774
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,037,157
Patent Claims:	1. A method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase comprising administering to a human in need of such treatment a therapeutically effective amount of a combination of said drug or a pharmaceutically acceptable salt thereof and ritonavir or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol , taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017. 3. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017. 4. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343. 5. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir. 6. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478. 7. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639. 8. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343. 9. A method for increasing human blood levels of a drug which is metabolized by cytochrome P450 monooxygenase comprising administering to a human in need of such treatment a therapeutically effective amount of a combination of said drug or a pharmaceutically acceptable salt thereof and ritonavir or a pharmaceutically acceptable salt thereof. 10. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol , taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017. 11. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017. 12. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343. 13. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir. 14. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478. 15. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639. 16. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343. 17. A method for inhibiting cytochrome P450 monooxygenase comprising administering to a human in need thereof an amount of ritonavir or a pharmaceutically acceptable salt thereof effective to inhibit cytochrome P450 monooxygenase. 18. A method for inhibiting cytochrome P450 monooxygenase comprising contacting the cytochrome P450 monooxygenase with an amount of ritonavir or a pharmaceutically acceptable salt thereof effective to inhibit cytochrome P450 monooxygenase.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.